Inclusion Criteria:

1. Patients aged ≥ 18 year-old.

2. Histologically documented renal cell carcinoma.

3. One or two prior therapy with cytokines and/or VEFG-ligand inhibitors are permitted.

4. Patients with an indication to receive everolimus treatment

5. Patients able and willing to give written informed consent, before the first
screening procedure.

Exclusion Criteria:

1. Patients currently receiving chemotherapy or immunotherapy

2. Prior treatment with temsirolimus

3. Contraindication in everolimus :

- Hypersensitivity to the active substance, to other rapamycin derivatives or to
any of the excipients.

- Patients with severe hepatic impairment (Child-Pugh class C)

- Patients with rare hereditary problems of galactose intolerance, Lapp lactase
deficiency or glucose-galactose malabsorption should not take this medicinal
product.

4. Pregnant or breastfeeding women

5. Patients unwilling to or unable to comply with the protocol.